Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease

HJ Li, SY Lin, FJ Lin, CS Hung… - Current Medical Research …, 2021 - Taylor & Francis
Objective We compared the effectiveness and safety outcomes of non-vitamin K antagonist
oral anticoagulants (NOACs) and warfarin in patients with AF and VHD, as these patients …

Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data

Z Xue, Y Zhou, C Wu, J Lin, X Liu, W Zhu - Heart Failure Reviews, 2020 - Springer
The role of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention
remains unclear in Asian patients with atrial fibrillation (AF). Therefore, we performed a meta …

The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular …

YH Chan, KT Lee, YW Kao, CY Huang, YL Chen… - PLoS …, 2019 - journals.plos.org
Background Previous studies indicated low-intensity warfarin (INR target of 1.5–2.5)
achieved reduced hemorrhage without increasing thromboembolism for Asians with non …

Effectiveness and safety of off-label dosing of non–vitamin K antagonist anticoagulant for atrial fibrillation in Asian patients

KN Lee, JI Choi, KY Boo, DY Kim, YG Kim, SK Oh… - Scientific reports, 2020 - nature.com
Non–vitamin K antagonist anticoagulants (NOACs) have been used to prevent
thromboembolism in patients with atrial fibrillation (AF) and shown favorable clinical …

Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillation

R Kreutz, S Kloss, D Enders, K Abdelgawwad… - International Journal of …, 2024 - Elsevier
Background Non-vitamin K antagonist oral anticoagulants (NOACs) have largely supplanted
vitamin K antagonists (VKAs) for oral anticoagulation in non-valvular atrial fibrillation …

Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in low-weight patients with atrial fibrillation

KH Chen, YY Hsu, CY Chou, CC Hsu… - Journal of Thrombosis …, 2024 - Springer
It remains unclear whether non-vitamin K antagonist oral anticoagulants (NOACs) are more
effective and safer than warfarin in low-weight patients with atrial fibrillation (AF). Here, we …

Inappropriate dose of nonvitamin-K antagonist oral anticoagulants: prevalence and impact on clinical outcome in patients with nonvalvular atrial fibrillation

C Godino, F Bodega, F Melillo, F Rubino… - Journal of …, 2020 - journals.lww.com
Background Limited real-world data are available regarding the outcome of patients treated
with inappropriate dose of nonvitamin-K antagonist oral anticoagulants (NOACs). Objective …

[HTML][HTML] Contemporary trend of reduced-dose non-vitamin K anticoagulants in Japanese patients with atrial fibrillation: A cross-sectional analysis of a multicenter …

T Ono, N Ikemura, T Kimura, I Ueda, H Tanaka… - Journal of …, 2019 - Elsevier
Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been widely used
to prevent stroke in non-valvular atrial fibrillation (NVAF) patients. Stringent monitoring is not …

Real‐World Comparative Effectiveness and Safety of Non‐Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country

P Mitsuntisuk, S Nathisuwan… - Clinical …, 2021 - Wiley Online Library
We aimed to compare effectiveness and safety of the non‐vitamin K antagonist oral
anticoagulants (NOACs) vs. warfarin for stroke prevention in nonvalvular atrial fibrillation …

Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation

YH Chan, LC See, HT Tu, YH Yeh… - Journal of the …, 2018 - Am Heart Assoc
Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …